Corvus Pharmaceuticals to Present at the 2019 Wedbush Healthcare Conference
August 07 2019 - 4:05PM
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of precisely targeted oncology therapies, today
announced that it will present at the 2019 Wedbush Healthcare
Conference in New York. The presentation will be on Wednesday,
August 14, 2019 from 1:20-1:50 pm ET.
A webcast of the presentation will be available live and for 90
days following the event. The webcast may be accessed via the
investor relations section of the Corvus website.
About Corvus Pharmaceuticals Corvus
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the development and commercialization of precisely
targeted oncology therapies. Corvus’ lead product candidates are
ciforadenant (CPI-444), a small molecule inhibitor of the A2A
receptor, and CPI-006, a humanized monoclonal antibody directed
against CD73 that exhibits immunomodulatory activity and blockade
of adenosine production. These candidates are being studied in
ongoing Phase 1 and 2 clinical trials in patients with a wide range
of advanced solid tumors. Ciforadenant is being evaluated in a
successive expansion cohort trial examining its activity both as a
single agent and in combination with Genentech’s atezolizumab, an
anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter
Phase 1/1b clinical trial as a single agent, in combination with
ciforadenant, and with pembrolizumab. The Company’s third clinical
program, CPI-818, an oral, small molecule drug that has been shown
to selectively inhibit ITK, is in a multicenter Phase 1/1b clinical
trial in patients with several types of T-cell lymphomas. For more
information, visit www.corvuspharma.com.
INVESTOR CONTACT: Leiv Lea Chief
Financial Officer Corvus Pharmaceuticals, Inc. 650-900-4522
LLea@corvuspharma.com
MEDIA CONTACT: Sheryl Seapy W2O
pure +1 213-262-9390 sseapy@purecommunications.com
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Sep 2023 to Sep 2024